Karuna Therapeutics Inc expected to post a loss of $2.11 a share - Earnings Preview

Karuna Therapeutics

31/10/2022 18:04

* Karuna Therapeutics Inc  KRTX.OQ   KRTX.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 2 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Karuna Therapeutics
Inc
is for a loss of $2.11 per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 18 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Karuna
Therapeutics Inc is $284​, above​ its last closing price
of $225.07. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -2.04       -2.09      -2.17     Missed  -3.6
 Mar. 31 2022  -2.18       -2.11      -1.95     Beat    7.6
 Dec. 31 2021  -1.66       -1.73      -0.94     Beat    45.8​
 Sep. 30 2021  -1.45       -1.44      -1.72     Missed  -19.4
 ​​Jun.        -1.30       -1.34      -1.17     Beat    12.5
 30 2021                                                
 Mar. 31 2021  -1.16       -1.13      -1.07     Beat    5.4​
 Dec. 31 2020  -0.90       -0.90      -0.89     Beat    0.6
 Sep. 30 2020  -0.79       -0.82      -0.71     Beat    13.6
 This summary was machine generated October 31 at 18:04 GMT.  All
figures in US dollars  unless otherwise stated